Takeda US chief reports 149,252 ADS RSU award

Takeda Pharmaceutical executive Rhonda Janice Pacheco, President of the U.S. Business Unit, filed an initial statement of ownership showing holdings of 149,252 American Depositary Shares.

Rhea-AI Filing Summary

Takeda Pharmaceutical executive Rhonda Janice Pacheco, President of the U.S. Business Unit, filed an initial statement of ownership showing holdings of 149,252 American Depositary Shares. This amount represents an award of restricted stock units, each convertible into one ADS, subject to a multi-year vesting schedule.

The RSUs vest in three equal time-based tranches: 49,750 shares on July 1, 2026, 49,750 shares on July 1, 2027, and 49,752 shares on July 1, 2028. All shares are reported as directly owned, reflecting a significant equity-based compensation grant that aligns the executive’s interests with long-term company performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pacheco Rhonda Janice

Role President, U.S. Business Unit

Type	Security	Shares	Price	Value
holding	American Depositary Shares	--	--	--

Holdings After Transaction: American Depositary Shares — 149,252 shares (Direct)

Footnotes (1)

1. F1. Represents an award of RSUs. Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (49,750 shares), July 1, 2027 (49,750 shares) and July 1, 2028 (49,752 shares).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Rhonda Pacheco’s Form 3 for Takeda (TAK) report?

The Form 3 reports Rhonda Janice Pacheco’s initial beneficial ownership of 149,252 American Depositary Shares of Takeda. These holdings come from a restricted stock unit award that vests over three years and are listed as directly owned equity-based compensation.

How many Takeda (TAK) ADSs are covered by Rhonda Pacheco’s RSU award?

The RSU award covers 149,252 American Depositary Shares of Takeda. Each restricted stock unit represents a contingent right to receive one ADS, subject to vesting conditions over a three-year schedule specified in the filing’s footnote.

What is the vesting schedule of Rhonda Pacheco’s Takeda (TAK) RSUs?

The RSUs vest in three installments: 49,750 shares on July 1, 2026, another 49,750 shares on July 1, 2027, and 49,752 shares on July 1, 2028. Vesting is strictly time-based according to the disclosed schedule.

Are Rhonda Pacheco’s Takeda (TAK) RSU-based ADS holdings direct or indirect?

The 149,252 American Depositary Shares tied to Rhonda Janice Pacheco’s RSU award are reported as directly owned. The filing does not indicate any trusts or intermediary entities, so ownership is classified as direct in the reporting details.

Does Rhonda Pacheco’s Takeda (TAK) Form 3 show any stock purchases or sales?

The Form 3 does not show open-market purchases or sales. It records an award of restricted stock units that convert into 149,252 American Depositary Shares on a time-based vesting schedule, reflecting compensation rather than market trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 06:15 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pacheco Rhonda Janice

(Last) (First) (Middle)

500 KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, U.S. Business Unit

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
American Depositary Shares	149,252(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of RSUs. Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (49,750 shares), July 1, 2027 (49,750 shares) and July 1, 2028 (49,752 shares).

Remarks:

Exhibit 24 Power of Attorney

	/s/ Max Heuer, by power of attorney, for Rhonda Pacheco	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)